Free Trial

Helix BioPharma (TSE:HBP) Stock Crosses Above 50 Day Moving Average - Time to Sell?

Helix BioPharma logo with Medical background

Key Points

  • Helix BioPharma's stock price rose above its 50-day moving average of C$1.02, reaching a high of C$1.38 during trading on Tuesday.
  • The company has a market capitalization of C$73.17 million and is focused on developing cancer therapies using its proprietary immuno-oncology technology.
  • Helix BioPharma's current P/E ratio is -1.45, indicating the company is not generating profits yet, reflecting its status as a clinical-stage biopharmaceutical firm.
  • Looking to export and analyze Helix BioPharma data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Helix BioPharma Corp. (TSE:HBP - Get Free Report) shares passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of C$1.02 and traded as high as C$1.38. Helix BioPharma shares last traded at C$1.38, with a volume of 6,673 shares trading hands.

Helix BioPharma Stock Up 8.9%

The firm has a market cap of C$77.94 million, a PE ratio of -1.54 and a beta of -0.84. The company's 50 day moving average price is C$1.05 and its two-hundred day moving average price is C$0.94.

Helix BioPharma Company Profile

(Get Free Report)

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.

See Also

Should You Invest $1,000 in Helix BioPharma Right Now?

Before you consider Helix BioPharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Helix BioPharma wasn't on the list.

While Helix BioPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

$15 Billion for Cybersecurity: The Government’s Next Big Push
Tesla’s Future Unleashed: Elon’s Robotics Move Changes Everything
Top Trades: Massive Gains and Costly Mistakes to Avoid

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines